Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Researcher Publications

Rita M. Musanti, PhD, ANP-BC, AOCNP

Selected Publications

Refereed Journal Articles

  1. Musanti, R., Cognetti, S., Chao, Y., Collins, K. (2017) Fitness and quality of life outcomes of cancer survivor participants in a community exercise program. JADPRO. Under Review.
  2. Chao, Y., Musanti, R. (2017). The feasibility of an exergaming program in the underserved older African-Americans. Western Journal of Nursing Research. Article first published online: January 8, 2017; https://doi.org/10.1177/0193945916687529
  3. Musanti, R., Murley, B. (2016). Community-based exercise programs for cancer survivors. Clinical Journal of Oncology Nursing.20(6): S25-S30.
  4. Musanti, R. (2016). How exercise can benefit patients with cancer. Clinical Journal of Oncology Nursing,20(6): S2.
  5. Musanti, R., Downing, M., Forrester, D.A., Fochesto, D., O'Keefe, P. (2015). Staff perceptions of patient visibility systems in acute care settings. Nursing management; 22(2):24-9.
  6. Musanti, R. (2012). A study of exercise modality and physical self-esteem in breast cancer survivors. Med Sci Sport Exerc, 44(2), 352 - 361.
  7. Musanti, R., O'Keefe, T., & Silverstein, W. (2012). Partners in caring: an innovative nursing model of care delivery. Nurs Adm Q, 36(3), 217-224.
  8. Knobf, T., Musanti, R., and Dorward J. (2007). Quality of Life Outcomes in Patients with Cancer. Seminars in Oncology Nursing. 23(4), 285-296.
  9. Aisner, J., Musanti, R., Beers, S., Smith, S., Locsin, S., & Rubin, E. H. (2003). Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Clin Cancer Res, 9(7), 2504-2509.
  10. Licitra, E. J., Vyas, V., Nelson, K., Musanti, R., Beers, S., Thomas, C., et al. (2003). Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res, 9(5), 1673-1679.
  11. Toppmeyer, D. L., Gounder, M., Much, J., Musanti, R., Vyas, V., Medina, M., Musanti, R., et al. (2003). A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit, 9(8), PI99-104.
  12. Redeker, N.S. and Musanti, R. (2002). Women'sphysical activity: conceptual issues. Topics in Rehabilitation. 18(1), 1-8.
  13. Poplin, E., Benson, A., 3rd, Musanti, R., Rubin, E., & Mulcahy, M. (2002). Pilot study of gemcitabine (10 mg/m(2) per min) and cisplatin. Cancer Chemother Pharmacol, 50(1), 80-83.
  14. Rubin, E. H., De Alwis, D. P., Pouliquen, I., Green, L., Marder, P., Lin, Y., Musanti, R.,et al. (2002). A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res, 8(12), 3710-3717.
  15. DiPaola, R. S., Rafi, M. M., Vyas, V., Toppmeyer, D., Rubin, E., Patel, J., Musanti-Zamek,R., et al. (1999). Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol, 17(7), 2213-2218.
  16. Ahmed, F., Vyas, V., Saleem, A., Li, X. G., Musanti-Zamek, R., Cornfield, A., et al. (1998). High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. J Chromatogr B Biomed Sci Appl, 707(1-2), 227-233.
  17. Gupta,E., Toppmeyer, D., Musanti-Zamek, R., Much, J., Ibrahim, N., Goodin, S., Kane., Aisner, J., Li, X-G., Haluska, P., Medina, M., Cornfield, A., Vyas, V., Natelson, E., Giovanella, B., Saleem, A., and Rubin, E.H. (1998). Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Terapeutics, 1, 292-301.
  18. Zannetti, A., Luly, P., Musanti-Zamek, R., & Baldini, P. M. (1997). Phosphatidylinositol- and phosphatidylcholine-dependent phospholipases C are involved in the mechanism of action of atrial natriuretic factor in cultured rat aortic smooth muscle cells. J Cell Physiol, 170(3), 272-278.

Book Chapters

  1. Forrester, D. A., Musanti, R. & Polansky, P. (2012). Systematic reviews and evidence-informed health care policy making. In C. Holly, Salmond, Susan Warner, Saimbert, Marie K. (Ed.), Comprehensive systematic review for advanced nursing practice. New York: Springer Publishing Co.
  2. Musanti, R. (2006). Fatigue. In K.Dow (Ed.) Nursing Care of Women with Cancer. St.Louis: Mosby- Elsevier.

Other Publications

  1. Musanti-Zamek, R. (2000). Off-site treatment. In A.D. Klimaszewski, J.L. Aiken, M.A. Bacon, S.A. DiStasio, H.E. Ehrenberger & B.A. Ford (Eds.) Manual for Clinical Trials Nursing. (pp. 233- 240). Pittsburgh: Oncology Nursing Press.
  2. Musanti-Zamek, R. (1998). New drug development: part 2: the origins of clinical trial regulation. Clinical Trials Newsletter, 9 (3). Pittsburgh: Oncology Nursing Press.
  3. Musanti-Zamek, R. (1998). New drug development: part 1: the origins of clinical trial regulation. Clinical Trials Newsletter, 9 (2). Pittsburgh: Oncology Nursing Press.

Return to member profile